Skip to main content
Health Canada approves Vertex's pediatric cystic fibrosis drug
12/14/2018

Vertex Pharmaceuticals received approval from Health Canada for Orkambi, or lumacaftor/ivacaftor, in patients ages 2 to 5 who have cystic fibrosis with two copies of the F508del mutation in the CFTR gene.

Full Story: